Loading...

2020: What does the future hold for the manufacturing and clinical landscape?

2020-02-18T15:38:59+00:00News|

What does the future hold for the manufacturing and clinical landscape? Pharma iQ asked Precision leaders Scott Marshall, PhD and Jeremy Schafer, PharmD, MBA. From gene therapy cures for chronic diseases to continuing price pressure on manufacturers, the role of machine learning to the role of companion diagnostics, their insights point the way to major developments in 2019.

 

To read the full article, click here

7 Therapeutic Game-Changers in 2019

2020-02-18T15:38:59+00:00News|

What top game-changing therapies will rock 2019 and deliver long-lasting consequences? Managed Healthcare Executive asked 7 industry leaders; Andrew Cournoyer, Precision for Value Vice President, Director, Payer Access Solutions, shares his vote.

To read the full article, click here

Payer-Pharma Collaboration Through Value-Based Contracts is Set to Accelerate

2020-02-18T15:39:09+00:00News|

 

Scientific advancements have created miracle cures for seemingly intractable diseases—along with astronomic price tags. Now, a new trend is exciting pharma, payers, physicians, patients and even analysts: linking drug reimbursement to patient outcomes. As this payment structure expands beyond chronic disease into specialty disease, how do you decide what a drug is worth?

(more…)

11 Books You Can’t Miss in 2019

2020-02-18T15:39:09+00:00News|

Managed Healthcare Executive asked 9 industry leaders—including Precision for Value experts Maureen Hennessey, Senior Vice President, Director of Value Transformation; Elizabeth Oyekan, Senior Advisory & Director, Quality and Population Health Solutions; and Linda Bolland, Senior Advisor—to share a must-read book (Hennessey shares three). The answers range from new fiction to business classics, but all give fresh insights into the healthcare industry.

To read the full article, click here

Biosimilars, Diabetes, and HCV Drug Uptake Expected to Spike With HHS Changes Restricting Safe Harbor Protection for PBMs and Drug Manufacturers, Experts Say

2020-02-18T15:39:09+00:00News|

Global Data News asks who will benefit from the new HHS proposal. Andrew Cournoyer, Precision for Value Vice President, Director, Payer Access Solutions, sees a potential boon for biosimilars and other lower-priced therapies and overall savings for those on expensive drug regimens.

  To read the full article, please see below

(more…)

HHS’s Proposed Rebate Rule Could Transform Pharma

2020-02-18T15:39:10+00:00News|

HHS has proposed a new rule targeting drug rebates given by pharmaceutical manufacturers to sponsors under Medicare Part D, Medicaid MCPs and the PBMs contracting with them. Todd Edgar, Precision for Value Senior Vice President, shares his insights in Radar on Specialty Pharmacy.

To read the full article, please see below

(more…)

2018 Trends of Innovative Therapies, Focus on Drug Prices Are Likely to Continue in ’19

2020-02-18T15:39:10+00:00News|

What will the pharma industry see in 2019? Market Access Spotlight asked five industry leaders, including Jeremy Schafer, PharmD, MBA, Senior Vice President of Specialty Solutions at Precision for Value. Answers start with groundbreaking therapies coupled with concerns about pricing and explore the aftermath of mergers and other industry inflection points.

(more…)

Load More Posts